TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, released clinical data from its Phase 1a trial of TTX-MC138 in poster 1025P at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The ongoing multicenter, open-label study evaluates safety, tolerability, pharmacokinetics, antitumor activity and exploratory biomarkers in patients with previously treated advanced solid tumors.
TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. The trial met its primary safety endpoint, with no dose-limiting toxicities observed and dose-dependent plasma exposure demonstrated across all evaluated doses. The company also reported disease stabilization and extended progression-free intervals in a subset of patients, supporting continued clinical evaluation of TTX-MC138.
The results matter because they provide the first clinical evidence that TTX-MC138, which targets microRNA-10b, a well-documented biomarker of metastasis, can be administered safely at doses that produce measurable drug exposure. For patients with advanced solid tumors who have already received prior treatment, the absence of dose-limiting toxicities and the observation of disease stabilization in some patients suggest a potential new therapeutic avenue. For TransCode, the data support advancing the program into later-stage testing, a critical step for a clinical-stage company seeking to attract partners or investors.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
The full press release can be viewed at https://ibn.fm/g3E2F. The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, delivering services that include editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
